Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 3/20 | 0.60 |
| ▸ | MAP3K14 | Q99558 | 13/20 | 0.52 |
| ▸ | PKD1 | P98161 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16532406 | 0.85 | PDE4A (0.47) | PDE4AMAP3K14PKD1 | |
| SCHEMBL16532313 | 0.84 | PDE4A (0.48) | PDE4AMAP3K14PKD1KCNH2GAA | |
| SCHEMBL17233522 | 0.83 | PDE4A (0.57) | PDE4AMAP3K14PKD1KCNH2MET | |
| SCHEMBL16532427 | 0.82 | MAP3K14 (0.56) | PDE4AMAP3K14PKD1RAB9ASMN1; SMN2 | |
| SCHEMBL16532425 | 0.82 | MAP3K14 (0.54) | PDE4AMAP3K14PKD1GAARAB9A | |
| SCHEMBL16532310 | 0.82 | ELANE (0.56) | PDE4AKCNH2 | |
| SCHEMBL16532419 | 0.81 | MAP3K14 (0.45) | PDE4AMAP3K14PKD1AURKARPS6KB1 | |
| SCHEMBL16532620 | 0.80 | MAP3K14 (0.52) | PDE4AMAP3K14GAARAB9ASMN1; SMN2 | |
| SCHEMBL16532418 | 0.79 | MAP3K14 (0.57) | PDE4AMAP3K14RAB9ASMN1; SMN2 | |
| SCHEMBL16532453 | 0.79 | MAP3K14 (0.46) | PDE4AMAP3K14PKD1AURKARPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-9605005-B2 | Alkynyl alcohols and methods of use | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605005-B2 | Alkynyl alcohols and methods of use | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-9605005-B2 | Alkynyl alcohols and methods of use | GENENTECH, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160200739-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (CA) | 2016-07-14 | — | — | US | disclosed |
| US-20160200739-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (CA) | 2016-07-14 | — | — | US | disclosed |
| US-20160200739-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (CA) | 2016-07-14 | — | — | US | disclosed |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2016-04-07 | — | — | US | disclosed |
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | GENENTECH, INC. (US) | 2015-03-05 | — | — | US | disclosed |
| WO-2015025025-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065482-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | PDE4A 1474/4885MAP3K14 514/4885PKD1 2902/4885 |
| US-20160096850-A9 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | PDE4A 1474/4885MAP3K14 514/4885PKD1 2902/4885 |
| US-20160200739-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | PDE4A 1474/4885MAP3K14 514/4885PKD1 2902/4885 |
| US-20170145034-A1 | ALKYNYL ALCOHOLS AND METHODS OF USE | NFKB2, NFKB1, RELA | PDE4A 1474/4885MAP3K14 514/4885PKD1 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.